Fig. 4From: Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in ItalyResults of probabilistic sensitivity analysis. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, PSA probabilistic sensitivity analysisBack to article page